UK approval for Pfizer’s JAK inhibitor Cibinqo
Treatment approved for adults and adolescents with moderate to severe atopic dermatitis
Read More
Tag: JAK inhibitor
AbbVie’s Rinvoq shows potential for atopic dermatitis
The selective and reversible JAK inhibitor hit all goals in the Phase III Measure Up study
Read More
US panel backs Pfizer’s Xeljanz for ulcerative colitis
US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
